medical researchFriday, July 17
Today's medical research brings a promising crossover: GLP-1 drugs, already known for diabetes and obesity, show real weight-loss benefit for schizophrenia patients battling antipsychotic side effects. Meanwhile, new data on focal prostate cancer therapy and air pollution's heart risks round out a day heavy on treatment and prevention angles.
A drug class best known for metabolic health is proving useful in psychiatry, and long-term cancer therapy data is filling gaps in treatment options.
Semaglutide at 1 mg/week led to 9 kg weight loss in adults with schizophrenia on antipsychotics, offering a practical option for a common, hard-to-treat side effect.
This 3,477-patient UK registry analysis provides rare 10-year outcomes for focal HIFU and cryotherapy in prostate cancer, supporting their use as alternatives to whole-gland treatment.
Two studies sharpen risk prediction for sudden cardiac arrest and coronary heart disease, while cannabis use gets a closer look for cardiovascular harm.
Cedars-Sinai's two studies aim to better identify who will have sudden cardiac arrest, a condition that kills most victims before they reach a hospital.
The China-PAR cohort links long-term PM2.5 exposure to coronary heart disease and heart attack, reinforcing the need for targeted air pollution control.
A review of new evidence ties cannabis use in young adults to inflammatory cardiovascular changes, and presents a prevention framework from the American Journal of Preventive Cardiology.
wellness roundup
sustainability roundup
open source roundup
real estate roundup
memoir roundup
literature roundup
